JP2017500306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500306A5 JP2017500306A5 JP2016538538A JP2016538538A JP2017500306A5 JP 2017500306 A5 JP2017500306 A5 JP 2017500306A5 JP 2016538538 A JP2016538538 A JP 2016538538A JP 2016538538 A JP2016538538 A JP 2016538538A JP 2017500306 A5 JP2017500306 A5 JP 2017500306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disorder
- pharmaceutical composition
- patient
- glyx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 14
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 8
- 239000000090 biomarker Substances 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 210000004556 brain Anatomy 0.000 claims 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 238000003384 imaging method Methods 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 238000002595 magnetic resonance imaging Methods 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 230000007177 brain activity Effects 0.000 claims 4
- 238000002599 functional magnetic resonance imaging Methods 0.000 claims 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000030990 Impulse-control disease Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000037326 chronic stress Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 230000008555 neuronal activation Effects 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 238000006213 oxygenation reaction Methods 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000001932 seasonal effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915835P | 2013-12-13 | 2013-12-13 | |
| US61/915,835 | 2013-12-13 | ||
| PCT/US2014/070340 WO2015089503A2 (en) | 2013-12-13 | 2014-12-15 | Methods of treating brain disorders or identifying biomarkers related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019153406A Division JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500306A JP2017500306A (ja) | 2017-01-05 |
| JP2017500306A5 true JP2017500306A5 (https=) | 2018-02-01 |
Family
ID=53371976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538538A Pending JP2017500306A (ja) | 2013-12-13 | 2014-12-15 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
| JP2019153406A Pending JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019153406A Pending JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160345855A1 (https=) |
| EP (2) | EP3079579A4 (https=) |
| JP (2) | JP2017500306A (https=) |
| CN (2) | CN106102762A (https=) |
| AU (2) | AU2014361822A1 (https=) |
| CA (1) | CA2933372A1 (https=) |
| IL (2) | IL246148A0 (https=) |
| MX (1) | MX2016007716A (https=) |
| WO (1) | WO2015089503A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018530593A (ja) * | 2015-10-16 | 2018-10-18 | ノースウェスタン ユニバーシティ | 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ |
| US20220024976A1 (en) * | 2019-01-11 | 2022-01-27 | Naurex Inc. | Salt and crystalline forms of rapastinel |
| CN110123342B (zh) * | 2019-04-17 | 2021-06-08 | 西北大学 | 一种基于脑电波的网瘾检测方法及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US20050273017A1 (en) * | 2004-03-26 | 2005-12-08 | Evian Gordon | Collective brain measurement system and method |
| US20090253982A1 (en) * | 2006-04-03 | 2009-10-08 | Jiongjiong Wang | Assessing subject's reactivity to psychological stress using fmri |
| CN101505745A (zh) * | 2006-06-15 | 2009-08-12 | 玛尔斯有限公司 | 改善认知功能的方法和组合物 |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| PL2485751T3 (pl) * | 2009-10-05 | 2014-10-31 | Univ Northwestern | GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie |
| US20140107037A1 (en) * | 2011-04-27 | 2014-04-17 | Northwestern University | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| WO2013106084A1 (en) * | 2012-01-09 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating alzheimer's disease |
-
2014
- 2014-12-15 MX MX2016007716A patent/MX2016007716A/es unknown
- 2014-12-15 WO PCT/US2014/070340 patent/WO2015089503A2/en not_active Ceased
- 2014-12-15 US US15/104,223 patent/US20160345855A1/en not_active Abandoned
- 2014-12-15 EP EP14870211.1A patent/EP3079579A4/en not_active Withdrawn
- 2014-12-15 JP JP2016538538A patent/JP2017500306A/ja active Pending
- 2014-12-15 AU AU2014361822A patent/AU2014361822A1/en not_active Abandoned
- 2014-12-15 CA CA2933372A patent/CA2933372A1/en not_active Abandoned
- 2014-12-15 CN CN201480068036.1A patent/CN106102762A/zh active Pending
- 2014-12-15 EP EP20174673.2A patent/EP3721799A1/en not_active Withdrawn
- 2014-12-15 CN CN202010314939.0A patent/CN111920412A/zh active Pending
-
2016
- 2016-06-09 IL IL246148A patent/IL246148A0/en unknown
-
2019
- 2019-08-26 JP JP2019153406A patent/JP2020007333A/ja active Pending
- 2019-11-13 AU AU2019264583A patent/AU2019264583A1/en not_active Abandoned
-
2020
- 2020-08-02 IL IL276431A patent/IL276431A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Butovsky et al. | Microglial signatures and their role in health and disease | |
| Oh et al. | SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death | |
| Bailliard et al. | Linking neuroscience, function, and intervention: A scoping review of sensory processing and mental illness | |
| Merlino et al. | Prevalence of ‘poor sleep’among patients with multiple sclerosis: an independent predictor of mental and physical status | |
| Wang et al. | miR-148b regulates proliferation and differentiation of neural stem cells via Wnt/β-catenin signaling in rat ischemic stroke model | |
| Won et al. | Elucidation of relevant neuroinflammation mechanisms using gene expression profiling in patients with amyotrophic lateral sclerosis | |
| JP2017500306A5 (https=) | ||
| Kim et al. | Neurological mechanisms of animal-assisted intervention in Alzheimer’s disease: a hypothetical review | |
| Kumar et al. | Neurological disorders and challenges in their Theranostics | |
| Holdhof et al. | hGFAP-positive stem cells depend on Brg1 for proper formation of cerebral and cerebellar structures | |
| EA201490548A1 (ru) | Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости | |
| JP2020007333A5 (https=) | ||
| DE602007006284D1 (de) | Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose | |
| IL185868A0 (en) | Human autism susceptibility gene encoding a transmembrane protein and uses thereof | |
| ATE424469T1 (de) | Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung | |
| Schneider et al. | Distinct forebrain regions define a dichotomous astrocytic profile in multiple system atrophy | |
| Fabisch et al. | Sinusoidal smooth pursuit eye tracking at different stimulus frequencies: position error and velocity error before catch-up saccades in schizophrenia and in major depressive disorder | |
| Le Boterff et al. | A tablet-based quantitative assessment of manual dexterity for detection of early psychosis | |
| Abdelaal et al. | Differential Expression of Exosomal MicroRNAs in Neurodegenerative Diseases | |
| Davtyan et al. | Transplantation of Human IPSC-derived Microglia Ameliorates Neuropathology and Circuit Dysfunction in Progranulin-Deficient Mice | |
| Vahia et al. | Successful aging-from research to practice | |
| Yin et al. | The dopaminergic polymorphisms in psychomotor retardation of depression: a pathway-based imaging genetics association study | |
| Liang et al. | WNT genes and their roles in traumatic brain injury | |
| Vayalapalli et al. | Evidence and Opportunities for Studying Sensorimotor Dysfunction Beyond Supratentorial Structures in Alzheimer’s Disease | |
| Danner et al. | Mutation of dop-1; dop-2; dop-3 in Caenorhabditis elegans Increases Nicotine Preference |